Could a simple steroid prevent strokes after brain aneurysm stenting?

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * （1）Aged ≥ 18 years; （2）Diagnosed with intracranial aneurysm (IA) via CTA, MRA, or DSA; （3）IA size ranging from 3 to 25 mm; （4）The patient and/or their authorized representative can understand the study purpose, voluntarily participate, and sign the informed consent form; （5）Patients scheduled to receive flow diverter treatment; （6）Patients willing to complete follow-up evaluations in accordance with the clinical study protocol. Exclusion Criteria: * （1）Patients with two or more multiple aneurysms who require secondary treatment within one month; （2）Female patients who are planning to become pregnant, are pregnant, or are breastfeeding; （3）Pre-onset modified Rankin Scale (mRS) score ≥ 2; （4）Patients complicated with systemic infectious diseases (latent or active stage), ulcerative colitis, diverticulitis, liver cirrhosis, myasthenia gravis, or ocular herpes simplex; patients with contraindications to glucocorticoids, such as active peptic ulcer and severe fungal infection; （5）Ruptured aneurysms, recurrent aneurysms, infectious aneurysms, dissecting aneurysms; complicated with arteriovenous malformation, dural arteriovenous fistula, spinal dural arteriovenous fistula, moyamoya disease, etc.; （6）Patients with symptomatic cerebrovascular stenosis ≥ 70%; （7）Patients who have had a stroke (cerebral hemorrhage, cerebral infarction) within the past 30 days; （8）Patients scheduled to undergo other surgical/interventional procedures within 30 days; （9）Patients with severe comorbidities unsuitable for anesthesia or surgical treatment, such as major diseases of the heart, lungs, liver, spleen, and kidneys, atrial fibrillation, brain tumors, severe active infections, disseminated intravascular coagulation, and severe psychiatric history; （10）Patients who cannot receive antiplatelet aggregation or anticoagulant therapy; （11）Hypersensitivity to methylprednisolone sodium succinate; （12）Patients receiving long-term hormone therapy (≥ 1 week) due to other comorbidities before surgery; （13）Patients taking hepatic enzyme-inducing drugs, such as barbiturates, rifampicin, rifabutin, carbamazepine, phenytoin, primidone, and aminoglutethimide; or patients taking hepatic enzyme-inhibiting drugs, such as erythromycin and ketoconazole; （14）Patients undergoing chronic hemodialysis or with severe renal insufficiency (glomerular filtration rate \< 30 ml/min or serum creatinine \> 220 μmol/L (2.5 mg/dl)); （15）Systolic blood pressure \> 180 mmHg or diastolic blood pressure \> 110 mmHg that is uncontrollable with oral antihypertensive drugs; （16）Blood glucose \< 2.8 mmol/L or \> 22.2 mmol/L; （17）Patients who have received a vaccine injection within the past month or have a plan for vaccination; （18）Patients who cannot understand or are unwilling to complete follow-up evaluations in accordance with the clinical study protocol; （19）Patients with advanced diseases with an expected life expectancy of \< 6 months; （20）Patients currently participating in other clinical trials.